168 related articles for article (PubMed ID: 26015163)
1. Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study.
Hamada S; Gulliford MC
Age Ageing; 2015 Jul; 44(4):566-73. PubMed ID: 26015163
[TBL] [Abstract][Full Text] [Related]
2. Drug prescribing during the last year of life in very old people with diabetes.
Hamada S; Gulliford MC
Age Ageing; 2017 Jan; 46(1):147-151. PubMed ID: 28181655
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus: A Population-Based Cohort Study Assessing Sex Disparities.
Wright AK; Kontopantelis E; Emsley R; Buchan I; Mamas MA; Sattar N; Ashcroft DM; Rutter MK
Circulation; 2019 Jun; 139(24):2742-2753. PubMed ID: 30986362
[TBL] [Abstract][Full Text] [Related]
4. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
[TBL] [Abstract][Full Text] [Related]
5. Use of cardiovascular medicines in newly treated type 2 diabetes patients: A retrospective cohort study in general practice.
Grimes RT; Ensor J; Bennett K; Henman MC
Prim Care Diabetes; 2016 Aug; 10(4):237-43. PubMed ID: 26654852
[TBL] [Abstract][Full Text] [Related]
6. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
[TBL] [Abstract][Full Text] [Related]
9. Use of drugs related to the treatment of diabetes mellitus and other cardiovascular risk factors in the Spanish population. The Di@bet.es study.
Rojo-Martínez G; Valdés S; Colomo N; Lucena MI; Gaztambide S; Gomis R; Casamitjana R; Carmena R; Catalá M; Martínez-Larrad MT; Serrano-Ríos M; Castaño L; Vendrell J; Girbés J; Franch J; Vázquez JA; Mora-Peces I; Urrutia I; Pascual-Manich G; Ortega E; Menéndez E; Delgado E; Bordiú E; Castell C; López-Alba A; Goday A; Calle A; Bosch-Comas A; Soriguer F
Rev Esp Cardiol (Engl Ed); 2013 Nov; 66(11):854-63. PubMed ID: 24773992
[TBL] [Abstract][Full Text] [Related]
10. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
11. Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register.
Ekström N; Miftaraj M; Svensson AM; Andersson Sundell K; Cederholm J; Zethelius B; Gudbjörnsdottir S; Eliasson B
Diabetes Obes Metab; 2012 Aug; 14(8):717-26. PubMed ID: 22364580
[TBL] [Abstract][Full Text] [Related]
12. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
13. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
[TBL] [Abstract][Full Text] [Related]
14. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
15. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
16. Time to modification of antidiabetic therapy in patients over the age of 65 years with newly diagnosed diabetes mellitus.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A
Diabetes Res Clin Pract; 2020 Apr; 162():108090. PubMed ID: 32088311
[TBL] [Abstract][Full Text] [Related]
17. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study.
Losada E; Soldevila B; Ali MS; Martínez-Laguna D; Nogués X; Puig-Domingo M; Díez-Pérez A; Mauricio D; Prieto-Alhambra D
Osteoporos Int; 2018 Sep; 29(9):2079-2086. PubMed ID: 29860664
[TBL] [Abstract][Full Text] [Related]
18. Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong.
Lau GS; Chan JC; Chu PL; Tse DC; Critchely JA
Ann Pharmacother; 1996 Mar; 30(3):232-7. PubMed ID: 8833556
[TBL] [Abstract][Full Text] [Related]
19. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
20. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
